Is technetium-99 m-pyrophosphate scintigraphy valuable in the diagnosis of cardiac amyloidosis?

Int J Card Imaging. 1990;5(4):227-31. doi: 10.1007/BF01797839.

Abstract

Amyloidosis is a systemic disease frequently involving the myocardium and leading to functional disturbances of the heart. Amyloidosis can mimic other cardiac diseases. A conclusive clinical diagnosis of cardiac involvement can only be made by a combination of different diagnostic methods. In 7 patients with myocardial amyloidosis we used a combined first-pass and static scintigraphy with technetium-99 m-pyrophosphate. There was only insignificant myocardial uptake of the tracer. The first-pass studies however revealed reduced systolic function in 4/7 patients and impaired diastolic function in 6/7 patients. Therefore, although cardiac amyloid could not be demonstrated in the static scintigraphy due to amyloid fibril amount and composition, myocardial functional abnormalities were seen in the first-pass study.

MeSH terms

  • Amyloidosis / diagnostic imaging*
  • Cardiomyopathies / diagnostic imaging*
  • Diphosphates*
  • Echocardiography
  • Electrocardiography
  • Humans
  • Technetium Tc 99m Pyrophosphate
  • Technetium*
  • Ventriculography, First-Pass

Substances

  • Diphosphates
  • Technetium Tc 99m Pyrophosphate
  • Technetium